Drug intelligence / Profile preview

SG1408

Development stage: Unknown
Lead developer: Shangjian Bio
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SG1408 is a humanized monoclonal antibody targeting B7-H3 (CD276), an immune checkpoint molecule that is highly expressed in various solid tumors and plays a role in tumor immune evasion. Developed by Sino-Health (Hangzhou) Biopharmaceutical, SG1408 is designed to bind to B7-H3 on tumor cells, thereby inhibiting its immunosuppressive function and potentially inducing antibody-dependent cellular cytotoxicity (ADCC) to eliminate cancer cells. The drug is currently being investigated in a Phase I clinical trial in China for the treatment of advanced malignant solid tumors in patients who have failed standard systemic therapies.

Targets

VEGFA (Vascular endothelial growth factor A)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on SG1408.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SG1408.

Explore the full profile